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BY-NC-ND license (http://creativecomAbstract KMUP-3 (7-{2-[4-(4-nitrobenzene) piperazinyl]ethyl}-1, 3-dimethylxanthine)
displays cardioprotection and increases cardiac output, and is suggested to increase cardiac
performance and improve myocardial infarction. To determine whether KMUP-3 improves out-
comes in hypoperfused myocardium by inducing Ca2þ sensitization to oppose protein kinase
(PK)G-mediated Ca2þ blockade, we measured left ventricular systolic blood pressure, maximal
rates of pressure development, mean arterial pressure and heart rate in rats, and measured
contractility and expression of PKs/RhoA/Rho kinase (ROCK)II in beating guinea pig left atria.
Hemodynamic changes induced by KMUP-3 (0.5e3.0 mg/kg, intravenously) were inhibited by
Y27632 [(R)-(þ)-trans-4-1-aminoethyl)-N-(4-Pyridyl) cyclohexane carboxamide] and ketanserin
(1 mg/kg, intravenously). In electrically stimulated left guinea pig atria, positive inotropy
induced by KMUP-3 (0.1e100mM) was inhibited by the endothelial NO synthase (eNOS) inhibi-
tors N-nitro-L-arginine methyl ester (L-NAME) and 7-nitroindazole, cyclic AMP antagonist
SQ22536 [9-(terahydro-2-furanyl)-9H-purin-6-amine], soluble guanylyl cyclase (sGC) antagonist
ODQ (1H-[1,2,4] oxadiazolo[4,3-a] quinoxalin-1-one), RhoA inhibitor C3 exoenzyme, b-blocker
propranolol, 5-hydroxytryptamine 2A antagonist ketanserin, ROCK inhibitor Y27632 and KMUP-
1 (7-{2-[4-(2-chlorobenzene) piperazinyl]ethyl}-1, 3-dimethylxanthine) at 10mM. Western blot-
ting assays indicated that KMUP-3 (0.1e10mM) increased PKA, RhoA/ROCKII, and PKC translo-
cation and CIP-17 (an endogenous 17-kDa inhibitory protein) activation. In spontaneous righteclare no conflicts of interests.
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56 C.-P. Liu et al.atria, KMUP-3 induced negative chronotropy that was blunted by 7-nitroindazole and atropine.
In neonatal myocytes, L-NAME inhibited KMUP-3-induced eNOS phosphorylation and RhoA/
ROCK activation. In H9c2 cells, Y-27632 (50mM) and PKG antagonist KT5823 [2,3,9,10,11,12-
hexahydro-10R- methoxy-2,9-dimethyl-1-oxo-9S,12R-epoxy-1H-diindolo(1,2,3-fg:30,20,10-kl)
pyrrolo(3,4-i)(1,6)benzodiazocine-10-carboxylic acid, methyl ester] (3mM) reversed KMUP-3
(1e100mM)-induced Ca2þ-entry blockade. GPCR agonist activity of KMUP-3 appeared opposed
to KMUP-1, and increased cardiac output via Ca2þ sensitization, and displayed cardioprotection
via cyclic GMP/PKG-mediated myocardial preconditioning in animal studies.
Copyright ª 2016, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).Introduction
Xanthine-based KMUP-3 (7-{2-[4-(4-nitrobenzene)
piperazinyl]ethyl}-1, 3-dimethylxanthine) has shown the
benefits in myocardiac infarction [1]. Here, the mecha-
nisms involved in cardioprotection and associated with the
mechanistic action of KMUP-3 were further addressed
in vitro. By contrast, KMUP-1 (7-{2-[4-(2-chlorobenzene)
piperazinyl]ethyl}-1, 3-dimethylxanthine), with similar
chemical structure, was also explored because it shows the
opposite G-protein-coupled receptor (GPCR) agonist activ-
ity to KMUP-3 [2e5]. This study aimed to investigate the
role of Ca2þ sensitization in improving cardiac performance
via GPCR and phosphodiesterase (PDE). Cardioprotection
and vasorelaxation via NO/cyclic GMP (cGMP)/protein ki-
nase (PK)G are required to prevent pressure overloading in
patients with hypoperfused myocardium [6]. Treatment
with a vasodilatory NO/cGMP enhancer with Ca2þ sensiti-
zation activity to increase cardiac output would be bene-
ficial for hypoperfused myocardium.
This study investigated whether KMUP-3, a PDE-3/PDE-
4/PDE-5 inhibitor that increases left ventricular systolic
blood pressure (LVSP) and atrial inotropy, is therapeutically
preferable to each class of PDE inhibitor for improving
hypoperfused myocardium, in addition to its proven bene-
ficial effects on the airways [7e9]. GPCR antagonism and
PDE inhibition in the cardiovascular and lipid systems have
been reported previously for KMUP-1 [10e17]. Here, we
explored the use of KMUP-3 as a GPCR agonist for the first
time, and found that it had the opposite effects of CGRP
antagonist KMUP-1. Whether KMUP-3 increases the principal
cyclic AMP (cAMP)/cGMP signal transduction pathways via
GPCRs or cardiac PDE inhibition remains to be proven [7].
Since RhoA/Rho kinase (ROCK) mediates Ca2þ sensitization,
we explored the activation of RhoA/ROCK by KMUP-3
[16e18]. Overstimulation of cardiac myocytes by cAMP/
Ca2þ is associated with excessive workloads, which in-
creases mortality in patients with hypoperfused myocar-
dium. Ca2þ sensitization, attributable to PKs, including
PKA, PKC, and RhoA/ROCK expression, the upstream
signaling of myosin light chain phosphatase (MLCP), re-
quires a protective strategy to avoid cardiac over-
stimulation [19]. This realization has caused a paradigm
shift in pharmacotherapy for congestive heart failure (CHF)
from cardiotonic to cardioprotective therapy [6e12]. ROCK
activation/Ca2þ-sensitization activity of KMUP-3, in
contrast to ROCK inactivation/Ca2þ-desensitization activityof KMUP-1, could be a potential mechanism for car-
dioprotection via increasing cardiac perfusion [10,20].
RhoA is a small GTP-binding protein controlled by guanine
exchange factors, which catalyzes the exchange of GDP for
GTP [8]. RhoA/ROCK is involved in cardiac contraction and
may be an interesting drug target [22e24]. ROCK has also
been shown to cause cardiac hypertrophy by raisingworkload
[23]. Although there is much evidence that activation of
RhoA is deleterious to the heart, RhoA may have the ability
to protect cardiomyocytes by signaling through Akt [24].
Theoretically, Ca2þ sensitization by RhoA/ROCK to increase
inotropydoesnot requiremuch intracellularCa2þ, in contrast
to the requirements for Ca2þ-binding to troponin [6].
GPCR agonists/antagonists are composed of flexible
structures and have been difficult to evaluate [25]. To date,
GPCRs have been activated by thrombin and lysophospha-
tidic acid in vascular smooth muscles [26]. Cardiac GPCRs,
including adrenergic and serotonergic receptors, are
innervated by the nervous system. To examine the benefits
of increasing cardiac output with GPCR agonist activity and
increasing cardioprotection with PKG in CHF, we investi-
gated the effects of KMUP-3 on hemodynamic/inotropic
activity, Ca2þ entry, cGMP/PKG enhancement, and protein
expression. The possibility of overcoming the heart failure
by means of the GPCR-mediated positive inotropic action of
KMUP-3, PDE inhibition, and cGMP/PKG-mediated car-
dioprotection were explored in this study.
Methods
Animals
Hartley guinea pigs of both sexes (350e500 g) and Wistar
rats (200e250 g) were provided by the National Laboratory
Animal Breeding and Research Center (Taipei, Taiwan) and
housed under constant temperature and controlled illumi-
nation at Kaohsiung Medical University, Kaohsiung, Taiwan.
Neonatal rats were obtained from copulation between
healthy male and female rats. Food and water were avail-
able ad libitum. This study was approved by the Animal
Care and Use Committee at Kaohsiung Medical University.
Measurement of Ca2D entry in H9c2 cells
To measure calcium current through L-type Ca2þ channels,
whole cell patch-clamp electrophysiology was used in rat
Cardioprotection and cardiac performance 57heart-derived H9c2 cells as previously described [23,24].
H9c2 cells were placed in a recording dish and perfused
with a bath solution containing 135mM tetraethylammo-
nium chloride, 1.8mM CaCl2, 2mM MgCl2, 10mM glucose,
and 10mM HEPES (pH 7.4, Tris). A recording electrode was
pulled from borosilicate glass (resistance: 4e7 MW), and
the pipette was coated with sticky wax close to the tip to
reduce capacitance, backfilled with pipette solution con-
taining 140mM CsCl, 1mM EGTA, 1mM MgCl2, 5mM Na2ATP,
and 5mN HEPES (pH 7.2, Tris) and gently lowered onto a
smooth muscle cell. Negative pressure was briefly applied
to rupture the membrane and a giga-ohm seal was
obtained.
H9c2 cells were clamped at 80 mV with step de-
polarizations (300 milliseconds) from 80 mV to 0 mV to
evoke whole-cell calcium current. Voltage-clamped cells
were equilibrated for 15 minutes prior to experimentation.
Membrane currents were recorded on an Axopatch 700A
amplifier (Axon Instruments, Union City, CA, USA), filtered at
1 kHz using a low-pass Bessel filter, digitized at 5 kHz, and
stored on a computer for subsequent analysis with Clampfit
9.0 (SUNNY, CA, USA). Following equilibration, calcium cur-
rent was monitored in the presence and absence of KMUP-
3 (1mM, 10mM, and 100mM). To ascertainwhether PKGor ROCK
signaling was involved in the KMUP-3-induced decreases in
calcium current, H9c2 cells were incubated for 15
minutes with a combination of KMUP-1 (10mM) and PKG
antagonist KT5823 [2,3,9,10,11,12- hexahydro-10R-
methoxy-2,9-dimethyl-1-oxo-9S,12R- epoxy-1H-diin-
dolo(1,2,3-fg:30,20,10-kl) pyrrolo(3,4-i)(1,6)benzodiazocine-
10-carboxylic acid, methyl ester] (3mM) or ROCK inhibitor
Y27632 [(R)-(þ)-trans-4-1-aminoethyl)-N-(4-Pyridyl) cyclo-
hexane carboxamide] (50mM). All electrical recordings were
performed at room temperature [21] and recordings of cal-
cium current each group were performed in triplicate.Hemodynamic measurements
Hemodynamic measurements were carried out in male
Wistar rats weighing 300e350 g, anesthetized with pento-
barbital sodium (40 mg/kg, intraperitoneally). Both KMUP-
3- and sham-treated animals were anesthetized for the
same length of time. Polyethylene tubing (PE50) was placed
in the trachea to keep the airway patent, and rats
continued to breathe spontaneously while hemodynamic
and cardiovascular functions were recorded. Vascular
catheters (PE50) were placed in the femoral arteries to
measure mean arterial blood pressure (MABP) and heart
rate (HR). Changes of MABP and HR caused by KMUP-3 were
recorded from the femoral artery with a pressure trans-
ducer (Model P50; Gould, Oxnard, CA, USA) connected to a
Pressure Processor Amplifier (Model 13-4615-52; Gould). A
femoral vein was used for intravenous administration of
KMUP-3. A specialized transducer tip catheter was placed in
the right carotid artery and advanced into the left ventricle
of the heart for measurement of LVSP or contractility.
Maximal rate of pressure development (dp/dt) at 50 mm
Hg, an index of cardiac contractility, was derived from the
left ventricular pressure trace. Post-hoc vascular resistance
was calculated as MABP/peripheral cardiac output [9]. Body
temperature was monitored throughout the experimentand maintained between 37C and 37.5C using a heating
pad.
Each dose of active drug was administered as a 20-
minute infusion in a series of escalating doses dissolved in a
5% dextrose water vehicle. After termination of the high-
dose infusion, animals were observed for 20 minutes.
KMUP-3 HCl was infused at 0.03 mg/kg/20 minutes, 0.05 mg/
kg/20 minutes and 0.075 mg/kg/20 minutes for the mea-
surement of Free Acid-Binding Protein (FABP), intraperito-
neally injected at 0.03 mg/kg, 0.05 mg/kg, and 0.1 mg/kg
for the measurement of MABP and HR, and infused by
intravenous injection for 2 minutes at 0.5 mg/kg, 1.0 mg/
kg, and 3 mg/kg dissolved in 5% dextrose water vehicle
(2 mL) for the measurement of LVSP, ABP, dp/dt, and HR.
The primary hemodynamic variables were calculated using
commercial software and a signal processing workstation.
Animals were randomly divided into one of six treatment or
vehicle groups. After the completion of the surgical pro-
tocol, animals were allowed to stabilize for 1 hour, and
baseline data were collected at 5-minute intervals for
30 minutes before treatment. Three tissue samples from
each group were used in the experiments.Organ bath experiments and tissue procurement
Guinea pigs were killed by a blow on the head. Their hearts
were quickly excised and trimmed of excess tissues. The
atrium was carefully removed and placed at room tem-
perature (20e25C) in a Krebs solution composed of NaCl
113mM, KCl 4.8mM, CaCl2 2.2mM, KH2PO4 1.2mM, MgCl2
1.2mM, NaHCO3 25mM, and dextrose 11.0mM, which was
bubbled with a 95% O2 þ 5% CO2 mixture, followed by
separation of the right and left atrium for subsequent ex-
periments. Three tissue samples from each group were
used in the experiments.Spontaneously beating right atrium
The spontaneously beating right atrium was dissected from
the heart and mounted in a 10-mL organ bath with one end
fixed and the other end connected to a force displacement
transducer (Model FT03; Grass, Quincy, MA, USA). The fre-
quency of contraction was measured on a separate channel
by a tachometer (Model S77-26; Coulbourn, Allentown, PA,
USA) connected to a high-speed videograph (AT L19-69;
Coulbourn). These experiments were carried out at 32.5C
in Krebs solution. The atrium strip was prestretched to a
baseline tension of 0.5 g and equilibrated for 90 minutes in
aerated (95% O2 þ 5% CO2) Krebs solution before the
experimental protocols were initiated. The atria were then
allowed a 30e60-minute washout period to restabilize.
KMUP-3 (0.1mM, 1.0mM, 10mM, and 100mM) was then cumu-
latively added to the organ bath. To examine the possible
involvement of NO and cAMP/cGMP in the action of KMUP-3
(0.1mM, 1.0mM, and 10mM) on spontaneously beating atria,
the beating atria were preincubated with atropine (1mM)
and N-nitro-L-arginine methyl ester (L-NAME; 100mM),
respectively. Three tissue samples from each group were
used in the experiments.
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Quiescent left atria were dissected free of connective tis-
sues and mounted in an organ bath under a resting tension
of 0.5 g. Organs were bathed at 32.5C in aerated Krebs
solution and electrically stimulated with 1 Hz at 2-second
intervals via two platinum electrodes placed at either side.
The positive inotropic effect was measured by determining
the cumulative concentrationeresponse curves in the
presence of KMUP-3 (0.1mM, 1.0mM, 10mM, and 100mM). To
examine the possible involvement of NO and cAMP/cGMP in
the action of KMUP-3 on electrically stimulated beating
atria, preincubation with Y27632 (1mM and 10mM), pro-
pranolol (1mM), L-NAME (100mM), 7-nitroindazole (100mM),
and ketanserin (1mM) was performed for 15 minutes prior to
adding KMUP-3 to measure the development of beating
force and heart rate for 10 minutes. Three tissue samples
from each group were used in the experiments.
Protein extraction and Western blotting analysis
After incubation with test agents in an organ bath, isolated
atria were frozen and pulverized to a fine powder at the
temperature of liquid nitrogen. Atrium powders were then
homogenized in protein extraction reagent (Pierce
Biotechnology, Rockford, IL, USA) by sonication. The sam-
ples were sonicated for 10 seconds three times and
centrifuged at 20,000 g at 4C for 30 minutes. The protein
concentrations of supernatants were determined using
bovine serum albumin as the standard. The cell extracts
were then boiled in a ratio of 4:1 with sample buffer [Tris
100mM, pH 6.8; glycerol 20%, sodium dodecyl sulfate (SDS)
4%, and bromophenol blue 0.2%]. Electrophoresis was per-
formed using 10% SDS-polyacrylamide gel electrophoresis
(PAGE) and transferred to nitrocellulose membranes (Milli-
pore, Billerica, MA, USA). Membranes were blocked with
Tris-buffered saline (TBS; 20mM Tris and 137mM NaCl, pH
7.6) containing 0.1% Tween 20 (TTBS) and 5% nonfat milk at
room temperature for 1 hour, washed with TTBS, and then
incubated overnight at 4C in the appropriate primary
antibody for PKARI, RhoA, ROCKII, p-CIP-17 (an endogenous
17-kDa inhibitory protein), CPI-17, and PKG1a1b. The mem-
branes were washed in TTBS before being incubated with
horseradish-peroxidase-conjugated antibody against
mouse, goat, or rabbit immunoglobulin G for 1 hour.
Membranes were then washed in TTBS and developed with
enhanced chemiluminescence to detect the specific anti-
gen. The intensity of the bands was measured by densi-
tometry. Endothelial NO synthase (eNOS) or phosphorylated
eNOS (p-eNOS) was extracted from the cell culture of rat
neonatal myocytes, pulmonary artery ring and aortic ring
(2e3 mm) and measured by western blotting [11]. Three
tissue samples from each group were used in the
experiments.
PK, ROCKII, and CIP-17 expression and
pretreatment of beating left atrium
To examine whether KMUP-3 affects protein expression in
beating atrium, PKA, ROCKII, PKG and phosphorylated CIP-
17 were measured by Western blotting. To examinewhether KMUP-3 affected crosstalk among ROCK and PKA,
PKC and PKG, Y27632 (0.1mM, 1mM, 10mM, and 100mM) or L-
NAME (10mM) were added to a beating atrium in the organ
bath for 15 minutes, followed by protein extraction. Three
tissue samples from each group were used in the
experiments.PKC translocation of beating left atrium
To determine the effect of KMUP-3 on PKCa translocation,
isolated left beating atrium was incubated with KMUP-3
(0.1e10mM) for 30 minutes. Frozen left atrium was pulver-
ized to a fine powder at the temperature of liquid nitrogen
for preparation of cytosolic and membrane fractions. Iso-
lated left atrial tissues were then homogenized by a soni-
cator (XL-2020; Heat Systems Ultrasonic, Plainview, NY,
USA) at 4C in 1 mL homogenization buffer containing 20mM
TriseHCl (pH 7.5), 1mM dithiothreitol, 5mM EGTA, 2mM
EDTA, 0.5mM phenylmethylsulfonyl fluoride, 20mM leu-
peptin, and 20mM aprotinin. The cytosol fractions were
obtained by collecting the supernatants after centrifuging
the cells at 100,000 g for 45 minutes at 4C. The pellets
were resonicated in homogenizing buffer with 1% Triton X-
100, centrifuged again at 100,000 g for 45 minutes at 4C,
and the supernatants collected as membrane fractions. The
extracts for cytosol and membrane fractions were dena-
tured by heating at 90C for 10 minutes in sampling buffer,
and an aliquot containing 20 mg total protein was subjected
to 10% SDS-PAGE. After migration, proteins were trans-
ferred onto polyvinylidene difluoride transfer membranes
(Millipore), and the membranes were successively incu-
bated at room temperature with 5% (w/v) nonfat dry milk in
TBS for 1 hour, and then incubated with primary antibody at
4C overnight. Protein was detected with horseradish-
peroxidase-conjugated secondary antibody (BD Trans-
duction Laboratories, San Jose, CA, USA). At the end of the
incubation, the membranes were extensively washed with
TBS. The immunoreactive bands were detected by chem-
iluminescence (ECL) reagents (PerkinElmer Life Sciences).
Three PKC expressions from each group were measured.RhoA activation of neonatal myocytes
RhoA activation was determined using an affinity precipi-
tation assay, which binds only the active GTP-bound form of
Rho. Subconfluent neonatal rat myocytes were grown to
85e90% confluence, cells were exposed to KMUP-3 with 10%
fetal bovine serum for 90 minutes at 37C before addition
of lysis buffer (25mM HEPES, pH 7.5, 150mM NaCl, 1% Igepal
CA-630, 10mM MgCl2, 1mM EDTA and 10% glycerol, 1 Ag/mL
aprotinin, 10 Ag/mL leupeptin, and 1mM Na3PO4) for
15 minutes at 4C. Cell lysates were clarified by centrifu-
gation at 13, 000 g at 4C for 10 minutes, and equal volumes
of lysates were incubated with agarose-conjugated rhote-
kin-Rho binding domain (RBD) for 45 minutes at 4C and
then washed three times with lysis buffer. Agarose beads
were boiled in SDS-PAGE sample buffer to release active
RhoA and samples were resolved on a 12% polyacrylamide
gel followed by immunoblotting with anti-Rho A (Clone 55).
Six RhoA expressions from each group were measured.
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Neonatal rat myocytes were incubated with KMUP-3
(0.1e10mM) in incubation plate wells for 24 hours and
terminated by adding 10% trichloroacetic acid. Intracellular
cAMP and cGMP concentrations were assayed as previously
described [6]. The cAMP and cGMP levels were determined
by a commercially available radioimmunoassay kit subse-
quently (GE Healthcare, Little Chalfont, Bucks, UK).
Compounds
The hydrochloride salt of KMUP-3, synthesized in this lab-
oratory, was used in all experiments [1]. SQ 22536 [9-(ter-
ahydro- 2- furanyl)-9H-purin-6-amine], L-NAME, and KT5823
were purchased from Cayman Chemical Co. (Ann Arbor, MI,
USA). Y27632, atropine, ketanserin, and 7-imidazole were
all obtained from SigmaeAldrich, Inc. (St. Louis, MO, USA).
Anti-PKCa, anti-eNOS and anti-phospho-eNOS (Ser1177)
antibody were obtained from BD Transduction Laboratories
and Cell Signaling Technology (Beverly, MA, USA), respec-
tively. Anti-PKARI and anti-PKG1 antibodies were purchased
from Calbiochem (San Diego, CA, USA). Anti-RhoA antibody
was obtained from Santa Cruz Biotechnology (Santa Cruz,
CA, USA). Anti-ROCKII, anti-phospho CPI-17 and anti-CPI-17
antibodies were obtained from Upstate Biotechnology
(Lake Placid, NY, USA). All drugs and reagents were dis-
solved in distilled water unless otherwise stated. KMUP-3
hydrochloride was dissolved in 5% glucose distilled solu-
tion. Serial dilutions were made with distilled water.
Statistical evaluation
All data are expressed as the mean  standard error. Sta-
tistical differences were determined by independent and
paired Student t test in unpaired and paired samples,
respectively. Whenever a control group was compared with
more than one treated group, one-way or two-way analysis
of variance was used. When analysis of variance manifested
a statistical difference, results were further analyzed with
Dunnett’s or Tukey’s test. A p value < 0.05 or p < 0.01 were
considered to be significant. Data analysis and figure plot-
ting were done using SigmaPlot software version 8.0 (Chi-
cago, IL, USA) and SigmaStat version 2.03 (Chicago, IL, USA)
run on an IBM compatible computer.
Results
Cardiac Ca2D entry blockade
In rat heart-derived H9c2 cells, KMUP-3 (1e100mM)
concentration-dependently reduced inward currents
(Figures 1A and 1B). The combination of KMUP-3 (10mM)
with KT5823 (3mM) or Y27642 (50mM) restored the reduced
currents (Figures 1Ce1F).
LVSP, dP/dt, MABP, and HR
As shown by the trace recordings in Figures 2Ae2D, intrave-
nous infusion of KMUP-3 (0.5e3 mg/kg; intravenously) dose-dependently increased LVSP, dp/dt and MABP within 2 mi-
nutes in anesthetized rats. Pretreatment with intravenous
Y27642 and ketanserin at 1 mg/kg respectively inhibited the
effects induced by KMUP-3 (1 mg/kg, intravenously). Intra-
venous perfusion of KMUP-3 (0.03e0.075 mg/kg/
min20minutes) dose-dependently increasedMABPandHR,
due to agonist activity of GPCR, particularly b-adrenergic
receptor (AR) activity (Figures 2E and 2F). Intraperitoneal
injection of KMUP-3 (0.0 3e0.1 mg/kg) dose-dependently
increased MABP and HR (Figures 2G and 2H).
Spontaneously beating right atria
As shown in Figures 3A and 3B, KMUP-3 (0.1e30 mM)
concentration-dependently increased inotropic and
decreased chronotropic effects in isolated spontaneously
beating right atrium. In contrast, milrinone (0.1e30mM)
increased both inotropic and chronotropic activities. The
beating frequency decreased by KMUP-3, due to PKG-
preconditioning or inhibited Ca2þ current in ventricle cells,
was upregulated by pretreatment with atropine (1mM) and 7-
nitroindazole (100mM; Figure 3C).
Electrically stimulated left atria
The inotropic effects of KMUP-3 and milrinone were studied
under electrical stimulation (1 Hz) at a constant rate. As
shown in Figure 3D, both KMUP-3 and milrinone (0.1e30mM)
concentration-dependently increased left atrium contrac-
tility. KMUP-3 was more potent than milrinone for
increasing contractility (p < 0. 05).
Pretreatment with the adenylyl cyclase inhibitor SQ
22536 and the sGC inhibitor ODQ [1H-(1,2,4) oxadia-
zolo(4,3-a) quinoxalin-1-one] inhibited KMUP-3-induced
contractility, suggesting the involvement of cAMP/cGMP
(Figure 3E). KMUP-3 (10mM) increased left atrium contrac-
tility and the effect was attenuated by 7-nitroindazole
(100mM; Figure 3F). Pretreatment with propranolol and
Y27632 at 1mM, C3 exoenzyme (50 mg/mL), ketanserin
(1mM), and L-NAME (100mM) all reduced KMUP-3-induced
positive inotropic activity in the left atria (Figures 3G and
3H).
RhoA/ROCKII and PKA
RhoA, ROCKII, and PKA expression were significantly
increased by KMUP-3 (0.1e10mM) in electrically stimulated
left guinea pig atria (Figures 4Ae4C).
PKC translocation and CPI-17 phosphorylation
The translocation of PKC fromcytosol tomembrane in guinea
pig left atrial cells was significantly increased by KMUP-3
(1mM; Figure 4D). However, pretreatment with Y27632 (1mM
and 10mM) nonsignificantly prevented KMUP-3-induced
translocation of PKC. Different expression ratios of cytosol/
cytosol þ membrane or membrane/cytosol þ membrane at
each concentration are shown in Figure 4D. KMUP-3 con-
centration-dependently increased the phosphorylation of
CPI-17 in electrically stimulated beating left guinea pig atria
(Figure 4E).
Figure 1. Effects of KMUP-3 on Ca2þ-entry currents in rat heart H9c2 cells. Cell patch-clamp electrophysiology was used to record
the inward currents. Recording trace (left side) of (A), (C), and (E) indicated effects of KMUP-3 and combinationwith Y27632 or KT5823
on inward currents. (A, B) KMUP-3 (1mM, 10mM, and 100mM) concentration-dependently decreased the inward currents. (C, D)
Combination with the protein kinase G antagonist KT5823 (3mM) restored the inward currents. (E, F) Combination with ROCK inhibitor
Y27632 (50mM) restored the inward currents, compared to KMUP-3 alone. Values are expressed as means  standard error (nZ 3).
* p < 0.05 versus control; ** p < 0.05 versus KMUP-3 (2 way repeated measures analysis of variance followed by Stu-
denteNewmaneKeuls test).KMUP-3Z 7-{2-[4-(4-nitrobenzene) piperazinyl]ethyl}-1, 3-dimethylxanthine; KT5823Z 2,3,9,10,11,12-
hexahydro-10R-methoxy-2,9-dimethyl-1-oxo-9S,12R-epoxy-1H-diindolo[1,2,3-fg:30,20,10-kl] pyrrolo[3,4-i][1,6]benzodiazocine-10-
carboxylic acid, methyl ester; ROCKZ Rho kinase; Y27623Z (R)-(þ)-trans-4-1-aminoethyl)-N-(4-pyridyl) cyclohexane carboxamide.
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As shown in Figure 5, KMUP-3 significantly increased the
expression of ROCKII (A) and PKA (B), but not PKG (C).
KMUP-3-induced expression of PKA and ROCK II was inhibi-
ted by Y27632 (1e100mM) but not PKG. Pretreatment with
L-NAME reduced the expression of PKG (Figure 5C).
eNOS/p-NOS, cAMP/cGMP, and GTP RhoA in
neonatal myocytes
To determine the role of the NO/cGMP pathway in heart,
neonatal rat myocyte protein was extracted followed by
Western blotting to measure the expression of eNOS and p-
eNOS (Figures 6A and 6B). Tissue extraction of eNOS in
western blotting analysis usually appears as a vague band-
ing that is difficult to separate. The illustrations are puz-
zling but actually accurate. KMUP-3 increased eNOS and p-
eNOS in neonatal rat cardiomyocytes and the effect wasreduced by L-NAME (100mM) pretreatment (Figures 6A and
6B). KMUP-3 increased both cAMP and cGMP. The latter was
increased more than the former (Figures 6D and 6E).RhoA activation of neonatal myocytes
As shown in Figure 6C, RhoA activation, determined using
an affinity precipitation assay which binds only the active
GTP-bound form of Rho, was increased by KMUP-3.ROCKII expression and vascular resistance
To determine whether the ROCKII activity of KMUP-3
increased vascular resistance, aorta and pulmonary artery
ring protein was extracted followed by Western blotting to
measure the expression of ROCKII and eNOS. We found that
KMUP-3 did not increase vascular ROCKII, but did increase
eNOS (Figure 7).
Figure 2. Hemodynamic effects of KMUP-3. (A) Recording traces of LVSP and MABP indicated that KMUP-3 (0.5 mg/kg, 1 mg/kg,
and 3 mg/kg, i.v.) increased cardiac output, as shown in: (B) LVSP; (C) dp/dt; (A, D, E, G) MABP; and (F, H), HR. KMUP-3-induced
effects were inhibited by pretreatment with Y27632 or ketanserin. Rats were treated with KMUP-3 (0.03e0.075 mg/kg, i.v.,
20 minutes or 0.03e0.1 mg/kg, i.p.). þ Y27632: KMUP-3 (1 mg/kg) þ Y27632 (1 mg/kg); þ ketanserin: KMUP-3 (1 mg/
kg) þ ketanserin (1 mg/kg). Values are expressed as means  standard error (n Z 3). * p < 0.05; ** p < 0.01 versus control;
*** p < 0.05 versus KMUP-1 (1 mg/kg) alone (2-way repeated-measures analysis of variance followed by StudenteNewmaneKeuls
test). dp/dt Z maximal rate of pressure development; HR = heart rate; i.v. Z intravenously; KMUP-3 Z 7-{2-[4-(4-nitrobenzene)
piperazinyl]ethyl}-1, 3-dimethylxanthine; LVSPZ left ventricular systolic pressure; MABPZ mean arterial blood pressure; Y27623
Z (R)-(þ)-trans-4-1-aminoethyl)-N-(4-pyridyl) cyclohexane carboxamide.
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Hemodynamic examination is crucial for assessing cardiac
performance in drug experiments for improving hypo-
perfused myocardium. KMUP-3, a PDE-3/PDE-4/PDE-5A in-
hibitor, has been used successfully to inhibit rat myocardial
infarction [1]. Healthy animal tissues are also required to
re-examine the benefits of KMUP-3 for improving outcomes
in hypoperfused myocardium using an experimental model
of electrically evoked muscle contraction and Ca2þ-current
influx. H9c2, a clonal myogenic cell line derived from em-
bryonic rat ventricles, was used to evaluate car-
dioprotection by an electrophysiologic technique, avoiding
noise from tissue-derived motion in experiments. In this
study, KMUP-3 displayed cardioprotective Ca2þ entry
blockade and increased LVSP, dp/dt, inotropy, and PKexpression, particularly RhoA/ROCKII, to correlate Ca2þ-
sensitization and cardiac motion. The crosslink between b-
AR/5-hydroxytryptamine (HT) receptor activation/inacti-
vation determines the effect of KMUP-3 on inotropy and
chronotropy [8,27e29]. Based on its Ca2þ sensitization,
KMUP-3 is a potentially valuable new cardiac GPCR agonist
that can therapeutically target cardiogenic shock or
myocardial hypoperfusion by increasing blood supply, tissue
oxygenation, and cardioprotection. Future experiments will
evaluate sarco/endoplasmic reticulum calcium-ATPase as
another effective method to determine the inotropic effect
of KMUP-3.
ROCK enhanced cardiac contractility via Ca2þ sensitiza-
tion, as it does in the vasculature. KMUP-3 activation of
RhoA/ROCK leads to Ca2þ sensitization and cardiac muscle
contractility even in the limited presence of Ca2þ [30].
Figure 3. Inotropic and chronotropic activities of KMUP-3 in spontaneously beating right and electrically stimulated beating left
atrium. (A) Positive inotropic activities of KMUP-3 and milrinone on beating right atrium. (B) Effects of KMUP-3 and milrinone on
frequency of beating right atrium. (C) Effects of KMUP-3 on frequency of beating right atrium and pretreatment with atropine (1mM)
or L-NAME (100mM). (D) Positive inotropic activities of KMUP-3 and milrinone on electronically stimulated left atrial contraction. (E)
Effects of pretreatment with SQ22536 (100mM) or ODQ (10mM) on KMUP-3-induced electronically stimulated left atrial contraction.
(F) Effects of pretreatment with 7-nitroindazole on KMUP-3-induced left atrial contraction. (G) Effects of pretreatment with
Y27632 (1.0mM), exoenzyme C3 (50 mg/mL) or L-NAME (100mM) on KMUP-3-induced left atrial contraction. (H) Effects of pre-
treatment with ketanserin (1mM) or propranolol (1mM) on KMUP-3-induced left atrial contraction. Values are expressed as
means  standard error (nZ 3). (AeE) and (GeI) * p < 0.05; ** p < 0.01; *** p < 0.001 versus KMUP-3; (GeI) share the same KMUP-3
data. (F) ** p < 0.01 versus control; # p < 0.05 versus KMUP-3 (2-way repeated-measures analysis of variance followed by Stu-
denteNewmaneKeuls test). KMUP-3 Z 7-[2-[4-(4-nitrobenzene) piperazinyl]ethyl]-1, 3-dimethylxanthine; L- NAME, N-nitro-L-
arginine methyl ester; ODQ Z 1H-[1,2,4] oxadiazolo[4,3-a] quinoxalin-1-one; SQ22536 Z 9-(terahydro- 2- furanyl)-9H-purin-6-
amine; Y27623 Z (R)-(þ)-trans-4-1-aminoethyl)-N- (4-pyridyl) cyclohexane carboxamide.
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KMUP-3 is suggested to increase atrial Ca2þ sensitization;
increased CPI-17 phosphorylation indicates upstream acti-
vation via PKC and elevated Ca2þ [31]. The PKC-potentiated
inhibitor protein of 17 kDa, called CPI-17, specifically in-
hibits MLCP. We suggest that KMUP-3 activates ROCKII and
also enhances CPI-17 (P-CPI-17) production through PKC
translocation to inhibit MLCP, leading to aortic and cardiac
Ca2þ sensitization.
The GPCRs are a large protein family of transmembrane
receptors. There are four pathways affecting the GPCR ac-
tivity of KMUP-3: (1) Y27632-sensitive activation of GPCRs by
RhoA/ROCK; (2) inactivation of b-AR type GPCRs via PKG-dependent PDE-5A; (3) propranolol-sensitive inactivation of
b-AR type GPCRs by PDE3/PDE4; and (4) ketanserin-sensitive
inactivation of 5-HT type GPCRs. Taken together, pathways
(1), (3), and (4) display cardiac GPCR agonist activity of
KMUP-3. We suggest that KMUP-3 at higher doses activates b-
AR-type GPCRs through inhibition of PDE-3/PDE-4 (2), and at
lower doses KMUP-3 enhances b-AR type inhibition of GPCRs
via PDE-5A inhibition/eNOS activation [8,9]. KMUP-3 can be
regarded as a cardiac GPCR agonist, while it increases LVSP,
dp/dt, inotropy, PKs, and particularly activation of RhoA/
ROCKII by inhibiting PDE-3/PDE-4/PDE-5. KMUP-1 inhibits
KMUP-3-induced atrial contractility, therefore, KMUP-1 is
suggested to be an antagonist of KMUP-3 via PDE and GPCRs.
1.37 ± 0.12
2.77 ± 0.10
3.56 ± 0.20
2.47 ± 0.55
Figure 4. Protein expression of (A) RhoA, (B) ROCKII, (C) PKA, (D) PKC, and (E) phosphorylated CPI-17, induced by KMUP-3 in
electrically stimulated guinea pig left atrium. In (D), the ratio of membrane to cytosol PKCa expression, compared to control,
indicates the extent of translocation; each peak indicates the percentage of total PKCa expression. Values are expressed as
means  standard error (n Z 3). * p < 0.05; ** p < 0.01; *** p < 0.001 versus control (2-way repeated-measures analysis of
variance followed by StudenteNewmaneKeuls test). CPI-17 Z an endogenous 17-kDa inhibitory protein; KMUP-3 Z 7-{2-[4-(4-
nitrobenzene) piperazinyl]ethyl}-1, 3-dimethylxanthine; L- NAME, N-nitro-L-arginine methyl ester; PK Z protein kinase;
ROCK Z Rho kinase.
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expression of RhoA/ROCK can be cAMP-dependent or cAMP-
independent. Both cAMP and cGMP lead to the phosphory-
lation of RhoA, resulting in RhoA inhibition [32]. In this
study, KMUP-3 activated cardiac RhoA/ROCK in the pres-
ence of increased cGMP and increased atrial contraction.
By enhancing cGMP/PKG, KMUP-1 may selectively inhibit
KMUP-3 GPCR agonist activity beyond PDE inhibition via
PKA.
There are three pathways contributing to the inotropic
and electrophysiological activity of KMUP-3: (1) RhoA/
ROCK-mediated sensitization; (2) cAMP/PKA-mediated
Ca2þentry; and (3) cGMP/PKG-mediated blockade of Ca2þ
entry. KMUP-3 predominately displays cGMP-dependent
Ca2þ blockade and ROCK-mediated Ca2þ sensitization ac-
tivity. The Ca2þ current inhibited by KMUP-3 were reversed
by ROCK inhibitor Y27632 and PKG inhibitor KT5823, indi-
cating that KMUP-3 is a ROCK activator and also a cGMP/
PKG-enhancer [8,28,31]. Increased eNOS/p-eNOS incultured neonatal rat myocytes and inhibited Ca2þ entry in
cardiac H9c2 cells indicate that KMUP-3 has L-type Ca2þ
blocking properties [28,30].
PKA increases open the L-type calcium channel, leading
to calcium influx and Ca2þ release from the sarcoplasmic
reticulum in cardiomyocytes via an excitationecontraction
coupling pathway. Continuous stimulation of cAMP/PKA
has calcium overloading potential and the resultant car-
diac arrhythmia and myocardial cell injury has been
considered the primary defect of PDE-3 inhibitors [33,34].
The electrically stimulated right atrial contractility shown
by KMUP-3 is inhibited by the sGC inhibitor ODQ, indicating
the involvement of cGMP. KMUP-3-induced positive ino-
tropy can be inhibited by SQ22536, indicating the
involvement of cAMP. The positive inotropy of KMUP-3,
inhibited by propranolol, is due to increased activation
of b-AR. Therefore, we suggest that the positive inotropy
of KMUP-3 is partly associated with the activation of b-AR
type GPCRs.
Figure 5. Effects of KMUP-3 on expression of (A) ROCKII, (B) PKA, and (C) PKG pretreatment with Y27632 and L-NAME in elec-
trically stimulated guinea pig left atrium. Values are expressed as means  standard error (nZ 3). ** p < 0.01; *** p < 0.001 versus
control; ## p < 0.01 versus KMUP-3 (2-way repeated-measures analysis of variance followed by StudenteNewmaneKeuls test).
KMUP-3Z 7-[2-[4-(4-nitrobenzene); piperazinyl]ethyl]-1, 3-dimethylxanthine; PKZ protein kinase; ROCKZ Rho kinase; Y27623Z
(R)-(þ)-trans-4-1-aminoethyl)-N-(4-pyridyl) cyclohexane carboxamide.
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electrically stimulated inotropy was inhibited by the ROCK
inhibitor Y27632, indicating ROCK involvement. Specif-
ically, pretreatments with C3 exoenzyme, a RhoA inhibitor,
inhibited KMUP-3 inotropy, indicating the selective activa-
tion of RhoA. Also, ketanserin, a 5-HT2A antagonist,
inhibited KMUP-3 inotropy, indicating 5-HT type GPCR
involvement. Therefore, we suggest that the positive ino-
tropy of KMUP-3 is partly associated with activation of
5-HT-type GPCRs and therefore RhoA/ROCKII [29,35,36].
In particular, C3 exoenzyme inhibited KMUP-3-induced
contractility, indicating that 5-HT type GPCR is selec-
tively activated to increase cardiac muscle contractility
[34,35]. However, Y27632 is a nonspecific ROCK inhibitor
displaying inhibition activity on PKs and thus able to reduce
PKA and PKCa translocation in electrically stimulated left
atrium [35].
Activation of NO/cGMP can stimulate the
hyperpolarization-activated pacemaking current in the
sinoatrial node of myocytes. NO acts presynaptically, dis-
playing vagally mediated bradycardia [36]. KMUP-3 con-
centration-dependently decreased the spontaneous
beating frequency of isolated guinea pig atria, indicatingnegative chronotropic activity possibly involving NO/cGMP.
To elucidate whether parasympathetic efferent activity is
involved in KMUP-3 negative chronotropy via the NO/cGMP
pathway, electrically stimulated left atria pretreated with
atropine and the NOS inhibitor 7-nitroindazole were
enhanced, and the results suggested NO/cGMP-dependent
acetylcholine release from the parasympathetic efferent
nervous system.
The positive inotropy of KMUP-3 in beating atria is
accompanied by increased PKA, PKC, and ROCKII expres-
sion, but not PKG. It is interesting that KMUP-3 more
effectively increased ROCKII than PKA in the presence of
PKG. However, increased PKC translocation by KMUP-3 was
inhibited by Y27632, indicating that Ca2þ sensitization does
not occur through ROCKII alone. In particular, crystal
structure investigation indicated that PKA is in a complex
with ROCK inhibitors; Y-27632, a relatively selective inhib-
itor of ROCK, inhibits PKC and cAMP-dependent PKA [35].
Accordingly, KMUP-3 causes crosstalk between PKA/PKC
and ROCKII in the beating atrium.
RhoA activation might protect cardiomyocytes from
ischemic damage [24]. Here, KMUP-3 exhibits car-
dioprotective effects via the expression of eNOS/cGMP/
Figure 6. Effects of KMUP-3 on expression of (A, B) eNOS/p-eNOS and (C) GTP RhoA, and levels of (D) cAMP and (E) cGMP in
cultured neonatal rat myocytes. In (A, B), KMUP-3-induced effects were inhibited by pretreatment with L-NAME. KMUP-3 increased
(A) eNOS, (B) p-eNOS, (C) GTP RhoA, (D) cyclic AMP, and (E) cyclic GMP. Values are expressed as means  standard error (n Z 3).
* p < 0.05; ** p < 0.01 versus control; ## p < 0.01 versus KMUP-3 (2-way repeated-measures analysis of variance followed
by StudenteNewmaneKeuls test). eNOS Z endothelial NO synthase; KMUP-3 Z 7-{2-[4-(4-nitrobenzene) piperazinyl]ethyl}-1,
3-dimethylxanthine; L- NAME, N-nitro-L-arginine methyl ester; p-eNOS Z phosphorylated eNOS.
Figure 7. Expression of ROCK and eNOS in the vascular system. Isolated (A) rat aorta and (B) pulmonary artery were incubated
with KMUP-3 (0.1mM, 1mM, and 10mM) for 90 minutes. eNOS expression in the aorta and pulmonary artery was increased by KMUP-3.
ROCK was nonsignificantly altered by KMUP-3. Values are expressed as means  standard error (n Z 3). * p < 0.05; *** p < 0.001
versus control (2-way repeated-measures analysis of variance followed by StudenteNewmaneKeuls test). eNOS Z endothelial NO
synthase; KMUP-3 Z 7-{2-[4-(4-nitrobenzene) piperazinyl]ethyl}-1, 3-dimethylxanthine; ROCK Z Rho kinase.
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did not increase aortic and pulmonary vascular ROCKII
expression, nor did it decrease ROCKII, indicating lack of
peripheral vascular resistance. However, caution is
required to prevent hypertensive crises by acute overdose.
The divide between Ca2þsensitization and Ca2þ entry
blockade in the heart requires careful dosage adjustment.
Milrinone decreased vascular resistance and caused
vascular hypotension beyond treating CHF, besides actions
resulting from NO release [36,37]. By contrast, KMUP-3
activates ROCKII to increase cardiac output without
inducing hypotension, while vasodilatory eNOS is increased
or activated. Hypotension in response to KMUP-3 might
be masked by increased LVSP due to PDE inhibition via PKA
and/or GPCRs agonist activity related to Ca2þ sensitization.
Vascular GPCR agonist activity, characterized by Ca2þ-
entry properties, has been shown by thrombin and lyso-
phosphatidic acid in vascular smooth muscle cells but not in
cardiac myocytes [25,26]. However, KMUP-3 did not in-
crease vascular contraction, nor activate vascular ROCK,
but did reduce cardiac Ca2þentry via cGMP/PKG in H9c2
cells. We suggest that the agonist activity of KMUP-3 is
inhibited by the GPCR antagonist KMUP-1.
In conclusion, KMUP-3 increases cardiac cGMP/PKG and
displays cardioprotective activity at lower doses and ac-
tivates GPCRs followed by Ca2þsensitization at higher
doses, along with PDE inhibition. The ability of KMUP-3 to
increase cardiac output via Ca2þ sensitization/PDE inhibi-
tion at higher doses and protect the ventricular cells by
Ca2þ-entry blockade via cGMP/PKG enhancement at lower
doses would be useful for the treatment of myocardial
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